Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6P2C8
UPID:
MED27_HUMAN
Alternative names:
Cofactor required for Sp1 transcriptional activation subunit 8; Mediator complex subunit 27; P37 TRAP/SMCC/PC2 subunit; Transcriptional coactivator CRSP34
Alternative UPACC:
Q6P2C8; O95401; Q4F964; Q5VTA4; Q5VTA5; Q9BU57; Q9NYR4; V9GYV9
Background:
Mediator of RNA polymerase II transcription subunit 27, also known as Mediator complex subunit 27, plays a pivotal role in the regulated transcription of nearly all RNA polymerase II-dependent genes. It acts as a bridge, conveying information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery, facilitating the assembly of a functional preinitiation complex.
Therapeutic significance:
The protein is linked to Neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia, suggesting its variants may influence the disease. Understanding the role of Mediator of RNA polymerase II transcription subunit 27 could open doors to potential therapeutic strategies for this disorder.